

# Duplex Study of the Carotid and Femoral Arteries of Patients with Systemic Lupus Erythematosus: A Controlled Study

TALIA WOLAK, EVGUENIA TODOSOU, GABRIEL SZENDRO, ARKADI BOLOTIN, BAT-SHEVA JONATHAN, DANIEL FLUSSER, DAN BUSKILA, SHAUL SUKENIK, and MAHMOUD ABU-SHAKRA

**ABSTRACT. Objective.** To identify atherosclerosis in the common carotid (CCA) and common femoral arteries (CFA) of patients with systemic lupus erythematosus (SLE) and matched controls.

**Methods.** Fifty-one consecutive patients with SLE were enrolled in the study. Controls were matched by age, sex, ethnicity, and atherosclerosis risk factors. All patients and controls underwent ultrasonic biopsy (U-B) of the CFA and CCA, a noninvasive screening technique that detects early atherosclerotic plaques and changes. The U-B features were classified and scored as follows: class A: normal (score 0); class B: interface disruption (score 2); class C: intima-media granulation (score 4); class D: plaque without hemodynamic disturbance (score 6); class E: stenotic plaque (score 8); and class F: plaque with symptoms (score 10). Total score was calculated. Classes A and B indicate an intact media; classes D to F point to a significant medial involvement; class C signifies a borderline lesion with a potential for regression to normal or progression to a plaque.

**Results.** Mean ages were 40.5 years for SLE patients and 41 years for controls ( $p = 0.6$ ). Ninety-six percent of the patients and controls were women. The mean disease duration of SLE was 8.65 years. Frequencies of risk factors among the SLE patients compared to controls were hypertension (30% vs 24%), smoking (23% vs 24%), and dyslipidemia (17.7% vs 17%). No patient had diabetes mellitus or family history of cardiovascular disease. A 3.17-fold increased rate of atherosclerotic plaques was detected in the SLE patients compared with controls (95% CI 1.08–10.9). Twenty-eight percent of SLE patients had at least a single class D–F lesion in one of the 4 vessels tested, compared with 10% in the control group ( $p = 0.02$ ). In addition, the mean total U-B score of the SLE patients was significantly higher than that of the controls (5.65 vs 3.14;  $p = 0.02$ ). Univariate analyses showed that the development of plaques in SLE was associated with a history of ischemic heart disease, hypertension, cardiovascular accident, and anemia. Multivariate analysis found plaques to be strongly associated with age, particularly in those older than 50 (OR 2.66,  $p = 0.000$ ).

**Conclusion.** Patients with SLE have a high rate of atherosclerotic changes compared to controls. The development of atherosclerosis is strongly associated with age. (J Rheumatol 2004;31:909–14)

## Key Indexing Terms:

SYSTEMIC LUPUS ERYTHEMATOSUS      DUPLEX      ULTRASONIC BIOPSY  
ATHEROSCLEROSIS      CAROTID ARTERY      FEMORAL ARTERY

From the Rheumatic Diseases Unit, Department of Medicine D, the Vascular Laboratory, and the Epidemiology Unit, Soroka University Medical Center and The Faculty of Health Sciences, Ben Gurion University, Beer-Sheva, Israel.

T. Wolak, MD, Instructor in Medicine; E. Todosoui, MD, Instructor in Medicine, Department of Medicine; G. Szendro, MD, Associate Professor of Surgery, Head, Department of Vascular Surgery and Vascular Laboratory; A. Bolotin, PhD, Epidemiology Unit; B-S. Jonathan, Registered Vascular Technologist, Vascular Laboratory; D. Flusser, MD, Lecturer, Rheumatic Disease Unit, Department of Medicine; D. Buskila, MD, Professor in Medicine, Head, Rheumatic Diseases Unit; S. Sukenik, MD, Professor in Medicine, Rheumatic Disease Unit, Head, Department of Medicine; M. Abu-Shakra, MD, Associate Professor in Medicine, Rheumatic Disease Unit.

Address reprint requests to Prof. M. Abu-Shakra, Department of Medicine D, Soroka University Medical Center, PO Box 151, Beer-Sheva, Israel.  
E-mail: mahmoud@bgumail.bgu.ac.il

Submitted January 8, 2003; revision accepted November 21, 2003.

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease of unknown cause that can affect the skin, joints, kidneys, lungs, nervous system, serous membranes, and other organs. During the last 3 decades, studies have identified atherosclerosis as a major contributor to the morbidity and mortality of patients with SLE<sup>1</sup>. Urowitz, *et al*<sup>2</sup> described the bimodal pattern of mortality in SLE, where late death in SLE is related to cardiovascular diseases. In a large mortality study<sup>3</sup>, 25% of all deaths were due to myocardial infarction (10.5%), cerebrovascular event (4%), rupture of abdominal aortic aneurysm (1%), congestive heart failure (2%), and sudden death (8.1%). Moderate to severe atherosclerosis was detected in 54% of 40 autopsies of SLE patients<sup>3</sup>. The prevalence of ischemic heart disease in SLE patients ranges

between 5% and 10%, and the mean age at diagnosis of ischemic heart disease was 48 years in one study<sup>4</sup>.

These data suggest that SLE is associated with premature and accelerated atherosclerosis. Early detection and management of atherosclerosis may reduce morbidity and improve survival of patients with SLE.

Ultrasonic biopsy (U-B) is a noninvasive technique able to recognize early atherosclerotic changes in the blood vessel wall<sup>5,6</sup>. The technique identifies alterations in the morphology of the posterior wall and atherosclerotic plaques. The sonographic findings are classified into 6 classes, A to F, each of which is scored on a scale from 0 to 10 (Table 1). In Class B there are only intimal changes with an intact media. Class C is a borderline lesion, with potential for both full regression to normal and progression to a plaque. The U-B classes have a predictive value for development of symptomatic cardiovascular disease<sup>5,6</sup>. Classes D and E are associated with an increased risk of subsequent cardiovascular events even when risk factors are corrected and antiplatelet prophylaxis is given<sup>6</sup>.

Our aim was to detect intimal and medial changes in the common carotid (CCA) and common femoral arteries (CFA) of patients with SLE and matched controls using U-B. In addition, we wanted to identify clinical and/or laboratory variables associated with the presence of atherosclerotic plaques in patients with SLE.

## MATERIALS AND METHODS

**Patients.** Fifty-one consecutive SLE patients were enrolled in the study. There were no exclusion criteria. All patients fulfilled the American College of Rheumatology (ACR) for classification of SLE<sup>7</sup> and were followed at the Soroka Medical Center Lupus Clinic. A complete history, examination, and laboratory evaluation were performed and recorded in a standard protocol.

**Controls.** Controls were matched by age, sex, ethnicity, and atherosclerosis risk factors (arterial hypertension, smoking, diabetes mellitus, family history of arteriosclerosis, hyperlipidemia, and total cholesterol and LDL cholesterol levels). Arterial hypertension was defined as systolic blood pressure > 140 and diastolic blood pressure > 95 mm Hg. Hyperlipidemia was defined as LDL level > 130 mg/dl or total cholesterol level > 240 mg/dl.

**U-B study.** All patients and controls underwent ultrasound study of the CCA and CFA, using an ATL Ultra-Mark 9, HDI duplex scanner, with a

high resolution 10 MHz probe. Both CCA and CFA were examined in the longitudinal plane, over 3 cm, immediately proximal to the bifurcation. By this technique the 3 planes of the posterior vessel wall could be identified and graded<sup>5</sup>. Measurements of the intima-media (I-M) complex thickness were made online on a frozen image using the built-in calipers. The complex thickness was defined as the average of 2 measurements selected at a distance of  $\pm 30$  mm proximal to the bifurcation where the adventitial line was the most uniform, measured on the far wall of the artery between the leading edge of the I line and the most distant edge of the adventitial line.

Ultrasound variables (dynamic range, depth range, power, reject, edge, grey scale, and smoothness) were constant during all examinations.

The ultrasonographer was blinded to the type of the examined subjects. Reproducibility and intraobserver variation were previously checked by repeat scanning of controls performed on different days. The coefficient of variation for the interobserver variability was 8.3% ( $r = 0.84$ , 95% confidence limits  $\pm 0.13$  of the observed values) and the intraobserver variability was 5.7% ( $r = 0.87$ ; 95% confidence limits  $\pm 0.06$  mm of the observed values).

**Outcome measures.** The outcome measures included: (1) I-M thickness of the posterior wall from intima to adventitia inclusive; (2) mean total U-B score of the 4 vessels, ranging between 0 and 40, where 0 indicates that all 4 vessels are in class A and 40 signifies symptomatic plaques in all vessels; (3) frequency of various U-B classes for each blood vessel; (4) frequency of the highest score (of the 4 vessels) for each patient, with each patient being given the highest of the scores of the 4 blood vessels examined by U-B.

**Predictors for atherosclerotic plaques in SLE patients.** SLE patients were stratified into 3 groups: Group I (no atherosclerosis) included patients with U-B classes A and B only in all vessels and no medial involvement; Group II (atherosclerosis plaque group) included SLE patients with classes D to F in at least one of the 4 blood vessels and significant medial involvement with atherosclerotic plaques; and Group III (intermediate group) included patients with class C, a borderline lesion with potential for progression or regression.

**Statistical analysis.** Statistical analysis was carried out using the Stata program<sup>8</sup>. Descriptive statistics, chi-square tests, Fisher's exact tests, and t tests were used to compare cases and controls. Univariate analysis and multivariate linear regression models were performed to identify clinical and laboratory variables associated with atherosclerosis.

## RESULTS

Table 2 shows the demographic features, atherosclerosis risk factors, levels of total and LDL cholesterol, and disease activity scores (SLE Disease Activity Index, SLEDAI, and Systemic Lupus International Collaborating Clinics, SLICC) of the SLE patients and controls. The mean age at U-B study, ethnic origin, and sex of SLE patients and controls were not statistically different. No patient or control

Table 1. Ultrasonic biopsy (U-B) classification.

| Class | Description  | Score |
|-------|--|-------|
| A     | Normal, 3 US layers clearly separated. No disruption of lumen-intimal interface for at least 0.5 cm.   | 0     |
| B     | Interface disruption: lumen-intimal interface disruption at intervals < 0.5 cm.  | 2     |
| C     | Intima-media granulation: granular echogenicity of deep, normally anechoic intimal-medial layer.   | 4     |
| D     | Plaque without hemodynamic disturbance: wall thickening and increased density involving all US layers. No hemodynamic disturbance on duplex. | 6     |
| E     | Stenotic plaque: as in D but with hemodynamic disturbance on duplex.   | 8     |
| F     | Stenotic plaque and presence of symptoms.  | 10    |

Table 2. Demographics and atherosclerotic (AS) risk factors of patients with SLE and controls.

|                                   | SLE, n = 51      | Controls, n = 47 | p    |
|-----------------------------------|------------------|------------------|------|
| Age, mean yrs (SD)                | 40.5 (14)        | 41.1 (14)        | 0.59 |
| F:M                               | 49:2             | 45:2             | 0.92 |
| Ethnicity (%)                     |                  |                  | 0.47 |
| Ashkenazi Jews                    | 32               | 39               |      |
| Sephardic Jews                    | 53               | 57               |      |
| Arab                              | 13               | 4                |      |
| Other                             | 2                |                  |      |
| SLE duration, mean yrs (SD)       | 8.65 (1.1)       |                  |      |
| AS risk factors                   |                  |                  |      |
| Hypertension                      | 30%              | 24%              | 0.63 |
| DM                                | 0                | 0                | 1    |
| Smoking                           | 23%              | 24%              | 1    |
| Family history                    | 0                | 0                | 1    |
| Hyperlipidemia                    | 17.7%            | 17%              | 1    |
| Mean LDL cholesterol, mg % (SD)   | 111              | 116              | 0.76 |
| Mean total cholesterol, mg % (SD) | 184              | 188              | 0.64 |
| Mean SLEDAI (SD)(range)           | 8.7 (8.2) (0–36) |                  |      |
| Mean SLICC, (SD) (range)          | 2.1 (2.6) (0–12) |                  |      |

DM: diabetes mellitus.

had diabetes mellitus. Mean SLEDAI score of the patients was 8.7 (range 0–36), and mean SLICC score was 2.1 (range 0–12).

The main clinical features of the SLE patients, occurring at any time during the SLE disease duration, included butterfly rash (43%), photosensitivity (66.6%), arthritis (58.8%), ischemic heart disease (11.8%), valvular heart disease (11.8%), congestive heart failure (4.0%), vein thrombosis (5.9%), livedo reticularis (17.6%), nephrotic syndrome (25.5%), renal failure (27.0%), cerebrovascular disease (cerebrovascular accident, CVA; 11.8%), seizures (5.8%), and cognitive dysfunction (8%).

Laboratory manifestations included antinuclear antibodies (98%), anti-DNA antibodies (74.5%), IgG anticardiolipin antibodies (aCL) (51%), and IgM aCL (53%).

The drugs given to the SLE patients during the course of the disease were nonsteroidal antiinflammatory drugs (39%), glucocorticosteroids (88%), antimalarials (90%), cyclophosphamide (23.5%), methotrexate (17.6%), and azathioprine (49%).

*I-M thickness.* Table 3 summarizes the I-M thickness of the CCA and CFA of patients and controls. The thickness of each vessel wall was measured at 2 different sites. Table 3 shows that I-M thicknesses of the vessels of cases and controls were not statistically different.

*Total U-B score.* The total U-B score for patients with SLE was 1.8 times higher than that of the controls. The mean total U-B score was 5.65 ( $\pm$  6.4) for the SLE patients compared to 3.14 ( $\pm$  5.82) in the controls ( $p$  = 0.02).

Table 4 shows the number of SLE patients and controls with the highest U-B score of the 4 vessels. Patients with SLE had significantly higher rates of AS plaques with an

Table 3. Intima-media thickness (mm) of the posterior wall from intima to adventitia of common femoral (CFA) and common carotid arteries (CCA) of SLE patients and controls.

|           | SLE Patients | Controls | p    |
|-----------|--------------|----------|------|
| Right CCA | 1.42         | 1.44     | 0.92 |
| Left CCA  | 1.31         | 1.31     | 0.98 |
| Right CFA | 1.38         | 1.23     | 0.27 |
| Left CFA  | 1.27         | 1.23     | 0.58 |

Table 4. U-B classes of SLE patients and controls.

| Highest U-B Score | SLE Patients, % | Controls, % |
|-------------------|-----------------|-------------|
| 0 (Class A)       | 37              | 64          |
| 2 (Class B)       | 24              | 9           |
| 4 (Class C)       | 12              | 17          |
| 6 (Class D)       | 24              | 8           |
| 8 (Class E)       | 4               | 2           |

$p$  = 0.027.

odds ratio (OR) of 3.17 [95% confidence interval (CI) 1.08–10.9,  $p$  = 0.034].

Twenty-eight percent of the SLE patients had an atherosclerotic plaque in at least one of the 4 vessels compared with only 10% in the control group (Table 4). Similarly, 67% of the controls were class A in all vessels compared with only 37% of the SLE patients. Although 6 SLE patients had a history of CVA, no association between the location of the plaque and the anatomic site of the CVA was found. Therefore, those plaques were given the score of 8 and not 10.

Table 5 shows the U-B scores of CFA and CCA in the cases and controls. There is a trend toward a higher frequency of atherosclerotic plaques in the SLE group compared to controls.

*Association between clinical and laboratory variables and atherosclerotic plaques.* Sixty-five demographic (age, disease duration, ethnicity), clinical (all main clinical features of SLE), laboratory (complete blood count, chemistry, lipid profile, anti-DNA, complements, IgG and IgM aCL), and therapeutic variables (steroids, cytotoxic drugs) were included in the univariate analysis. The analysis was conducted to compare variables of the SLE patients without atherosclerosis (Group I) with those with overt plaques (Group II) and those with intermediate lesions (Group III). Table 6 shows various variables of SLE patients found to be associated in the univariate analysis with the presence of plaques. Carotid and femoral plaques were strongly associated with age, hypertension, coronary artery disease, and CVA.

Sixteen variables (Table 6) were included in 2 multivariate regression models. In the first mode, patients were classified into 2 groups: those age 50 or above and those below age 50. In this model the development of atherosclerosis

was associated only with age > 50 (OR 2.66, 95% CI 1.63–4.35,  $p = 0.000$ ).

In a second model, the age of patients was included without stratification into age groups. In this model, atherosclerosis was significantly associated with age (regression coefficient = 0.031,  $p = 0.000$ ) and marginally associated with hypertension ( $p = 0.086$ ). No other variable was associated with atherosclerosis in either model.

## DISCUSSION

Later morbidity and mortality in SLE is largely caused by atherosclerosis<sup>1-3</sup>. The atherosclerotic process is usually widespread and may affect the aorta, coronary arteries, the common carotid, cerebral, and main arteries of the extremities<sup>2</sup>. Carotid duplex scanning is a noninvasive method for screening for both symptomatic and asymptomatic atherosclerosis. The detection of atherosclerotic plaques in the carotid arteries is associated with the presence of coronary artery disease, and atherosclerotic plaque is an independent predictor for myocardial infarcts<sup>5,6,9</sup>. Early detection of asymptomatic atherosclerotic disease allows early intervention and possibly prevention of symptomatic cardiovascular disease. Few studies have reported the frequency of atherosclerosis

Table 5. U-B classification of the CFA and CCA of SLE patients and controls. Results are expressed as percentages.

| Class   | Right CCA |          | Left CCA |          | Right CFA |          | Left CFA |          |
|---------|-----------|----------|----------|----------|-----------|----------|----------|----------|
|         | SLE       | Controls | SLE      | Controls | SLE       | Controls | SLE      | Controls |
| A and B | 85        | 87       | 81       | 76       | 75        | 89       | 79       | 90       |
| C       | 8         | 9        | 16       | 17       | 8         | 8        | 8        | 4        |
| D and E | 8         | 4        | 4        | 6        | 8         | 2        | 16       | 4        |

Table 6. Variables associated with atherosclerotic plaques (univariate analysis). Results are expressed as percentages unless otherwise defined.

| Variable                      | Group I (No AS) | Group II (AS) | Group III (Intermediate) | p     |
|-------------------------------|-----------------|---------------|--------------------------|-------|
| Mean age, yrs                 | 32.5            | 55.6          | 46.1                     | 0.00  |
| Disease duration > 5 yrs      | 45              | 72            | 33                       | 0.17  |
| MI/IHD                        | 3               | 35            | 0                        | 0.006 |
| Arthritis                     | 50              | 85            | 50                       | 0.09  |
| Brain hemorrhage              | 0               | 15            | 0                        | 0.06  |
| Organic brain syndrome        | 3               | 23            | 0                        | 0.07  |
| CVA                           | 3.1             | 31            | 0                        | 0.02  |
| Claudication                  | 0               | 15            | 0                        | 0.06  |
| Ischemic ulcers               | 3               | 15            | 33                       | 0.07  |
| Hypertension                  | 23              | 54            | 17                       | 0.009 |
| PVD                           | 0               | 15            | 0                        | 0.07  |
| Smoking                       | 17              | 31            | 33                       | 0.47  |
| Renal failure                 | 17              | 43            | 33                       | 0.18  |
| Anemia                        | 89              | 31            | 60                       | 0.001 |
| Mean total cholesterol, mg/dl | 170             | 209           | 193                      | 0.06  |
| Mean LDL level, mg/dl         | 102             | 126           | 114                      | 0.25  |

MI/IHD: myocardial infarction/ischemic heart disease, CVA: cardiovascular accident, PVD: pulmonary vascular disease.

sclerotic plaques in patients with SLE. Petri, *et al*<sup>10</sup> found the frequency of AS plaques in SLE to be 8%. Manzi, *et al*<sup>11</sup> identified focal plaques in 40% of the carotid arteries of women with SLE. However, 15% of the women had known coronary artery disease or CVA. In the older age group, plaques were detected in 71% of women with SLE aged 55–64 years. In a recent study<sup>12</sup>, 37% of SLE patients had atherosclerotic plaques in the carotid arteries.

Our study is the first to scan the CFA in addition to the CCA. We also used U-B, which allows detection of early changes that occur in the vessel wall before the development of an overt plaque. This includes lumen-intimal interface disruption (U-B class B) and granular echogenicity of deep I-M layer (U-B class C).

In a series of 2000 asymptomatic individuals<sup>5</sup>, all subjects in the 10–29 age group were in class A, 7% in the 30–49 age group were in class B, and only 5% of individuals in the age group 40–49 had atherosclerotic plaques. Two hundred four asymptomatic subjects underwent a cardiac stress test. No patients in classes A and B had ischemic changes. However, a pathological stress test was observed in 6.3%, 25%, and 42% of subjects in classes C, D, and E, respectively. Fifty-five percent of symptomatic patients (class E) had ischemic changes in a stress test.

The significance of class B is not clear. B class differs from A class by the ultrasonic wall structure analysis and therefore, despite identical present-time clinical significance, gets a different score. In a 6 year followup, 27% of subjects progressed from class A to class B, while 13% progressed from class B to class C<sup>5</sup>.

In our study, patients with SLE were found to have a higher frequency of abnormal CCA and CFA. This was documented by the total U-B scores and the frequency of atherosclerotic plaques. The total U-B score for patients with SLE was 1.8 times higher than that of the controls. In addition, only 37% of the SLE patients had normal CCA and CFA by U-B scan (class A). A 3.17-fold increased rate of atherosclerotic plaques was detected in the SLE patients compared with controls (28% in SLE compared with 10% in controls). Similarly, Roman, *et al*<sup>12</sup> found the frequency of atherosclerotic plaques in their SLE patients to be 2.2 times higher than controls (37% vs 16%).

A few studies<sup>13,14</sup> have shown that patients with SLE had a higher I-M thickness compared with controls. However, those reports were based on few cases of SLE patients. We measured the I-M thickness at 2 different sites on each vessel wall. Our I-M thickness is higher than other published data. This is explained by our measurement technique that included the adventitial layer within the measured wall thickness. This way of measuring is inaccurate among an aged population with irregularity in the outer layer. However, our young study patients had very little adventitial irregularity. We found this wall thickness measurement to be more reproducible when online, onscreen analysis is done.

The I-M thickness measurements of the CFA and CCA of our SLE patients and controls were not significantly different. Roman, *et al*<sup>12</sup> found the I-M thickness was significantly greater in controls. The data indicate that I-M thickness is not a sensitive instrument for identifying early and asymptomatic atherosclerosis.

By univariate analysis, we found atherosclerotic plaques were associated with age, coronary artery disease, CVA, and hypertension. A trend was found to suggest higher levels of LDL and total cholesterol among patients who had atherosclerotic plaques.

Previous reports identified a link between plaques and various clinical variables. In a univariate analysis, Maksimowicz, *et al*<sup>15</sup> found an association between plaques and traditional risk factors including male gender, family history, smoking, hypertension, and high mean cholesterol. Another study<sup>12</sup> reported a link between plaques and pulmonary hypertension, Raynaud's phenomenon, postmenopausal status, hypertension, and duration of SLE. However, age eliminated all other factors in multivariate analysis.

In our study, the multivariate linear regression model found plaques to be associated only with age of the SLE patients. This observation indicates that plaques are more likely to develop late in the course of SLE. This finding indirectly supports the bimodal pattern of mortality in SLE, described by Urowitz, *et al*, 26 years ago<sup>2</sup>.

In summary, patients with SLE have a high frequency of abnormal CCA and CFA, manifested by early (pre-plaques) changes as well as atherosclerotic plaques. The development of atherosclerotic plaques is mainly associated with age, particularly in those over 50.

## REFERENCES

1. Bruce I, Gladman DD, Urowitz MB. Premature atherosclerosis in SLE. *Rheum Dis Clin North Am* 2000;26:257-78.
2. Urowitz MB, Bookman AAM, Koehler BE. The bimodal mortality pattern of SLE. *Am J Med* 1976;60:221-5.
3. Abu-Shakra M, Urowitz M, Gladman D, Gough J. Mortality studies in SLE. Results from a single center. Causes of death. *J Rheumatol* 1995;22:1259-64.
4. Manzi S, Meilahn EN, Rairie JE. Age-specific incidence rates of myocardial infarction and angina in women with SLE: comparison with the Framingham Study. *Am J Epidemiol* 1997;145:408-15.
5. Belcaro G, Renton S, Nicolaidis AN. Ultrasonic biopsy: a non-invasive screening technique to evaluate the cardiovascular risk and to follow up the progression and the regression of arteriosclerosis. *Vasa* 1991;20:40-50.
6. Belcaro G, Laurora G, Cesarone MR, De-Sanctis MT, Incandela L, Barsotti A. Progression of subclinical atherosclerosis in 6 years. Ultrasound evaluation of the average combined femoral and carotid bifurcation intima-media thickness. *Vasa* 1995;24:227-32.
7. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-7.
8. Stata Corp. Stata Software: Release 5.0. College Station, Texas: Stata Corp.; 1997.
9. Burke GL, Evans GW, Riley WA. Arterial wall thickness is

associated with prevalent cardiovascular disease in middle-age adults. The Atherosclerosis Risk in Communities (ARIC) study. *Stroke* 1995;26:386-91.

10. Petri M. Frequency of atherosclerosis detected by carotid duplex in SLE [abstract]. *Lupus* 1998;7 Suppl S1:64.
11. Manzi S, Selzer F, Sutton-Tyrrell K. Prevalence and risk factors of carotid plaque in women with SLE. *Arthritis Rheum* 1999;42:51-60.
12. Roman MJ, Shanker BA, Lockshin M, et al. Accelerated atherosclerosis in SLE: clinical correlates and time dependency [abstract]. *Arthritis Rheum* 2002;46 Suppl:S40.
13. Tiroch C, Taute BM, Babinsky K, Podhaisky H, Fleig WE, Keyszer G. Increased intima-media-thickness of the carotid artery as marker of arteriosclerosis in patients with RA and SLE [abstract]. *Arthritis Rheum* 2000;46 Suppl:S1371.
14. De Leeuw K, Freire B, Smit AJ, Kallenberg CGM, Bijl M. Premature atherosclerosis and endothelial dysfunction in SLE [abstract]. *Arthritis Rheum* 2000;46 Suppl:S44.
15. Maksimowicz K, Petri M, Magder L. Predictors of carotid atherosclerosis in SLE [abstract]. *Arthritis Rheum* 2000;46 Suppl:S32.